CE Information and Faculty Disclosures

• TARGET AUDIENCE
  These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.
  
  LEARNING OBJECTIVES

  • Apply available research evidence to individualize the selection and use of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Recognize the efficacy, including CNS activity, of the recently FDA-approved HER2-directed antibody-drug conjugate trastuzumab deruxtecan, and identify patients who are appropriate candidates for treatment with this drug.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive breast cancer.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Evaluate recently presented Phase III data documenting the benefit of the CDK4/6 inhibitor abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative localized breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
  • Recall the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with metastatic breast cancer.
  • Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations among patients with ER-positive metastatic breast cancer, and understand the FDA-approved indication for alpelisib in combination with fulvestrant in order to optimally employ this approach for postmenopausal patients with ER-positive, HER2-negative disease with PIK3CA mutations.
  • Implement a long-term clinical plan for the management of advanced HER2-negative and HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
  • Acknowledge the recent FDA approval of pembrolizumab in combination with chemotherapy as neoadjuvant treatment and continued as adjuvant monotherapy after surgery for high-risk localized triple-negative breast cancer.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component.
  NCPD credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Kathy D Miller, MD
  Ballvé-Lantero Professor
  Division of Hematology/Oncology
  Associate Director for Clinical Research
  The Indiana University Melvin and Bren Simon Cancer Center
  Indianapolis, Indiana
  
  Consulting Agreements: AbbVie Inc, Athenex; Contracted Research: Astex Pharmaceuticals, BBI Solutions, CytomX Therapeutics, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Merck, Roche Laboratories Inc.
  
  Kelly Leonard, MSN, FNP-BC
  Family Nurse Practitioner
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Lilly, Novartis and Seagen Inc.
  
  Release date: September 2021
  Expiration date: September 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

  TARGET AUDIENCE
  These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.
  
  LEARNING OBJECTIVES

  • Apply available research evidence to individualize the selection and use of neoadjuvant, adjuvant and extended adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Appraise the recent FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer, and identify patients who are appropriate candidates for treatment with this drug.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive breast cancer, and optimally integrate this novel regimen into current treatment algorithms.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Evaluate recently presented Phase III data documenting the benefit of the CDK4/6 inhibitor abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative early breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
  • Recall the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with metastatic breast cancer.
  • Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations among patients with ER-positive metastatic breast cancer, and understand the FDA-approved indication for alpelisib in combination with fulvestrant in order to optimally employ this approach for postmenopausal patients with ER-positive, HER2-negative disease with PIK3CA mutations.
  • Implement a long-term clinical plan for the management of advanced HER2-negative and HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
  • Acknowledge the recent FDA approval of pembrolizumab in combination with chemotherapy as neoadjuvant treatment and continued as adjuvant monotherapy after surgery for high-risk early-stage triple-negative breast cancer.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 1.5 contact hours is provided by RTP during the period of September 2021 through September 2022.
  
  This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1 contact hour is provided by RTP during the period of September 2021 through September 2022.
  
  This activity is awarded 1 ANCC pharmacotherapeutic contact hour.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSBreast2021/MTP3/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSBreast2021/MTP3/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSBreast2021/MTP3/Video.
  
  Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSBreast2021/MTP3/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSBreast2021/MTP3.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Carey K Anders, MD
  Professor of Medicine
  Medical Director of the Duke Center
  of Brain and Spine Metastases
  Duke Cancer Institute
  Durham, North Carolina
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics Inc, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning.
  
  Jamie Carroll, APRN, MSN, CNP
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Lilly, Novartis and Seagen Inc.
  
  Release date: October 2021
  Expiration date: October 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.